ProscaVax Vaccine Safe for Recurrent Prostate Cancer Patients, Phase 1a/1b Trial Shows October 4, 2017 ProscaVax, a cancer vaccine developed by OncBioMune Pharmaceuticals, is safe for the treatment of recurrent prostate cancer patients, data from a Phase 1a/1b trial shows.Read more.Source: Prostate Cancer News Today Prostate Cancer News
ProscaVax, a cancer vaccine developed by OncBioMune Pharmaceuticals, is safe for the treatment of recurrent prostate cancer patients, data from a Phase 1a/1b trial shows.Read more.Source: Prostate Cancer News Today
Donate Now
